GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (ASX:BIT) » Definitions » Notes Receivable

Biotron (ASX:BIT) Notes Receivable : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Biotron Notes Receivable?

Biotron's Notes Receivable for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Biotron Notes Receivable Historical Data

The historical data trend for Biotron's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Notes Receivable Chart

Biotron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biotron Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biotron Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Biotron Notes Receivable Related Terms

Thank you for viewing the detailed overview of Biotron's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotron Business Description

Traded in Other Exchanges
Address
56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron Headlines